Diligence memo · auto-generated · as of July 2, 2026
Anterios Inc
Anterios Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Anterios Inc operates in Biotechnology, based in NEW YORK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Anterios Inc has raised $17M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.2M on 2009-10-06.
Most recent recorded round closed around 2013-03-25.
Valuation (modeled)modeled
Provath models Anterios Inc at approximately $172M (range $5.2M–$933M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.08× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era. Within the normal band (108% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 13.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 65% of Biotechnology peers (4293 compared).
Modeled value ranks above 69% of those peers.
Closest niche peers: Dnanexus, Inc., Foresight Biotherapeutics, Inc., AuraSense Therapeutics, LLC, Zyomyx Inc, Champions Oncology, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.